342
Participants
Start Date
September 12, 2016
Primary Completion Date
August 22, 2019
Study Completion Date
September 17, 2019
Standard of care
Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
(1,3)-β-D-glucan guided therapy
Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
University Hospital Greifswald, Greifswald
University Hospital Hamburg-Eppendorf, Hamburg
University Hospital Schleswig-Holstein, Kiel
Hospital Oldenburg, Oldenburg
Hospital Emden, Emden
University Hospital Göttingen, Göttingen
University Hospital Frankfurt, Frankfurt
University Hospital Heidelberg, Heidelberg
Hospital Augsburg, Augsburg
HELIOS Klinikum Bad Saarow, Bad Saarow
University Hospital Bonn, Bonn
University Hospital Erlangen, Erlangen
University Hospital Halle, Halle
University Hospital Münster, Münster
Diakonie Klinikum, Siegen
University Hospital Würzburg, Würzburg
Jena University Hospital, Jena
University Hospital Leipzig, Leipzig
Center for Clinical Studies, University Hospital Jena, Germany
UNKNOWN
Dept. of Microbiology, University Hospital Erlangen, Germany
UNKNOWN
Institute of Medical Statistics, Computer Sciences and Documentation, University Hospital Jena, Germany
UNKNOWN
Federal Ministry of Education and Research, Berlin, Germany
UNKNOWN
Associates of Cape Cod, Inc., East Falmouth, MA, USA
UNKNOWN
Center for Sepsis Control and Care, Germany
OTHER